Companhia Siderurgica Nacional S.A. (SID)
Live price chart, market sentiment, and community perspectives for Companhia Siderurgica Nacional S.A. (NYSE: SID).
Live price chart, market sentiment, and community perspectives for Companhia Siderurgica Nacional S.A. (NYSE: SID).
Looking at the sell-side consensus for SID, we see a heavy 'Sell' rating anchored by 4 Sells and 7 Holds out of 11 analysts. However, the average 12-month price target was recently bumped to $1.54. From a market sentiment perspective, it reflects a classic disconnect between lagging fundamental scores and prospective recovery pricing.
On our desk, we are closely tracking the completion of the CSN Inova Ventures exchange offer. With over $1.01 billion of the 6.750% Senior Notes due 2028 tendered—representing nearly 77.5% of the total outstanding—the company has successfully substituted a large chunk of near-term maturities with 11.000% Senior Notes due 2030, paying out roughly $255.7 million in cash.
As a risk manager assessing SID's exposure in the basic materials sector, the year-to-date and 6-month drawdowns of over 47% demand stringent position sizing. Even though the current price range hovers around $0.89 to $0.98 with a $1B market cap, the high yield restructuring on the 2030 notes indicates lingering balance sheet pressure.
Evaluating the quantitative and alternative data signals, AltIndex places SID at an AI Score of 45/100, categorizing it strictly as a Hold. Fundamental sub-scores sit around 36/100, while brand and employment metrics hover near 50/100. It's a textbook profile of a distressed basic materials asset where momentum indicators remain deep in negative territory over a 6-month horizon.
From a quantitative standpoint, the order book volume remains quite thin on certain exchanges, making execution challenging for larger block sizes. The wide forecast spread—ranging from $0.84 on the low end to $2.21 on the high end—underscores an extreme divergence in terminal value assumptions among the 11 covering analysts.
Our equity research circle notes that despite the average price target ticking up marginally from $1.53 to $1.54, zero analysts are currently pounding the table with a Buy rating. The prevailing consensus is cautious, trapping the equity in a persistent holding pattern until clearer operational turnarounds materialize in upcoming Form 6-K filings.
Explore plasma cleansing, somatic organ swaps, and BCI.